콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

모든 문서 보기

Y0001075

Rifaximin for system suitability

European Pharmacopoeia (EP) Reference Standard

동의어(들):

Rifaximin, 4-Deoxy-4′-methylpyrido[1′,2′-1,2]imidazo[5,4-c]rifamycin SV, Rifacol

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C43H51N3O11
CAS Number:
80621-81-4
Molecular Weight:
785.88
MDL number:
MFCD00864973
UNSPSC 코드:
41116107
PubChem Substance ID:
329831249
NACRES:
NA.24

Grade

pharmaceutical primary standard

API family

rifaximin

제조업체/상표

EDQM

응용 분야

pharmaceutical (small molecule)

형식

neat

저장 온도

2-8°C

SMILES string

CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@@H](C)[C@@H](O)[C@@H](C)[C@H](O)[C@H](C)[C@H]([C@H]1C)C(=O)OC)c5c(nc6cc(C)ccn56)c4c3C2=O

InChI

1S/C43H51N3O11/c1-19-14-16-46-27(18-19)44-32-29-30-37(49)25(7)39-31(29)40(51)43(8,57-39)56-17-15-26(54-9)22(4)28(42(53)55-10)23(5)36(48)24(6)35(47)20(2)12-11-13-21(3)41(52)45-33(34(32)46)38(30)50/h11-18,20,22-24,26,28,35-36,47-50H,1-10H3,(H,45,52)/b12-11+,17-15+,21-13-/t20-,22+,23-,24-,26+,28+,35-,36-,43+/m1/s1

InChI key

HIYLTQREEOINNF-HTEWPBCCSA-N

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

애플리케이션

Rifaximin for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

포장

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

기타 정보

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

죄송합니다. 지금은 이 제품에 대한 COA이(가) 온라인에서 제공되지 않습니다.

도움이 필요하시면 연락하세요. 고객 지원 부서

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Stacy B Menees et al.
The American journal of gastroenterology, 107(1), 28-35 (2011-11-03)
Irritable bowel syndrome (IBS) affects 10-15% of the population, and treatment options are limited. Rifaximin is a minimally absorbed antibiotic that has shown efficacy in IBS patients. The objective of our study was to perform a meta-analysis and systematic review
Qian Jiang et al.
European journal of gastroenterology & hepatology, 20(11), 1064-1070 (2008-12-03)
To compare the positive and negative effects of rifaximin and nonabsorbable disaccharides in patients with hepatic encephalopathy. We used the method recommended by The Cochrane Collaboration to perform a meta-analysis of comparative randomized trials of rifaximin and nonabsorbable disaccharides. Seven
Darego O Maclayton et al.
The Annals of pharmacotherapy, 43(1), 77-84 (2008-12-19)
To review the effectiveness and safety of rifaximin in the treatment of hepatic encephalopathy (HE). MEDLINE (1990-October 2008) was searched using the terms rifaximin, rifamycins, hepatic encephalopathy, liver cirrhosis, and acute liver failure. Other sources included the bibliographies of pertinent
Filippo Cremonini et al.
Expert opinion on pharmacotherapy, 13(3), 433-440 (2012-01-19)
Few therapeutic options are available for irritable bowel syndrome (IBS). Lubiprostone is approved by the FDA for IBS with constipation, and alosetron in IBS with diarrhea (IBS-D). It has been proposed that alterations in the bowel microflora may play a
Herbert L DuPont
Expert opinion on pharmacotherapy, 12(2), 293-302 (2011-01-14)
Rifaximin is increasingly being used to treat acute and chronic gastrointestinal infections and disorders. The drug exerts its beneficial effect through a variety of gut-selective mechanisms involving the host intestinal microbiota. Abstracts of all publications listed in PubMed on the
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.